Abbisko Therapeutics Co Ltd (HKEX code: 02256.HK), a China-based biopharmaceutical company, announced on Tuesday that the US Food and Drug Administration (FDA) has approved PIMJETMI (pimicotinib), a small-molecule colony-stimulating factor 1 receptor (CSF-1R) inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumour (TGCT), for which surgical resection may cause worsening functional limitation or severe morbidity.
According to Abbisko, PIMJETMI is an orally available and potent small-molecule CSF-1R inhibitor independently developed by Abbisko Therapeutics, with global commercialisation rights granted to Merck KGaA, Darmstadt, Germany.
The US FDA approval marks the fourth NDA approval for PIMJETMI, following approvals in China by the National Medical Products Administration (NMPA) in December 2025, in Canada by Health Canada in June 2026, and in Switzerland by the Swiss Agency for Therapeutic Products (Swissmedic) in October 2026, further accelerating the global commercialisation plan. Upon the first commercial sale in the US, Abbisko will receive an additional milestone payment.
Abbisko is also eligible to receive double-digit royalties on global net sales of PIMJETMI, as well as potential payments relating to other regulatory, development, and commercial sales milestones.
FDA approval of PIMJETMI is based on primary and longer-term results from the global Phase III MANEUVER study and the Open-Label Extension.
The applications for PIMJETMI in the US, Canada and Switzerland were reviewed under Project Orbis, an international collaboration framework initiated by the FDA Oncology Center of Excellence to facilitate collaboration among participating regulatory authorities and accelerate the review of oncology products.
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Valneva reports 94% antibody persistence five years after single-dose chikungunya vaccination
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Energenesis Biomedical presents ENERGI-based approach to space anaemia at TASTI 2026
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
Illumina expands MRD research portfolio with ultrasensitive sequencing technology